Amendments to and Listing of the Claims:

Please amend claims 1 and 27, without prejudice, cancel claim 3, without prejudice, as set forth in the following listing of claims, which replaces all prior listings of claims.

1. **(Currently Amended)** A film-shaped medicament for buccal administration of galanthamine or a salt or derivative thereof, said medicament comprising at least one layer containing a cholinergic active substance or a combination of at least two cholinergic active substances, said active substance(s) being selected from the group consisting of galanthamine, pharmaceutically acceptable salts of galanthamine, galanthamine derivatives and their pharmaceutically acceptable salts, and said film-shaped medicament being soluble in aqueous media and/or rapidly disintegrating in aqueous media, but not being mucoadhesive, wherein within thirty minutes after buccal administration of the medicament, the medicament releases such an amount of the cholinergic active substance(s) contained therein to the oral cavity that an effective plasma level is achieved.

2. (Previously Presented) The film-shaped medicament according to claim 1, wherein the layer or at least one of the layers has a polymer matrix serving as an active substance reservoir, the polymer matrix-containing layer has a polymer content of 5 to 95%-wt.

3-6. **(Cancelled)**

7. (Previously Presented) The film-shaped medicament according to claim 1, being of a bilayer or multilayer structure, with at least one of the layers containing the active substance.

8. (Previously Presented) The film-shaped medicament according to claim 1, wherein at least one of the layers has a retarded active substance release.

9. (Previously Presented) The film-shaped medicament according to claim 1, wherein the active substance-containing layer(s) has an active substance content of 0.1 to 30%-wt.

10. (Previously Presented) The film-shaped medicament according to claim 1, wherein the medicament contains galanthamine, or a salt or derivative of galanthamine, in combination with at least one further pharmaceutically active substance.

11. (Previously Presented) The film-shaped medicament according to claim 1, wherein the thickness of the layer is 0.01 to 5 mm.

12. (Previously Presented) The film-shaped medicament according to claim 1, containing one or more auxiliaries selected from the group consisting of fillers, colourants, emulsifiers, plasticizers, disintegration promoters, disintegrants (wick agents), wetting agents, sweetening and flavouring agents, preservatives, pH regulators, permeation-enhancing substances and antioxidants.

13. (Cancelled)

14. (Previously Presented) The method according to claim 27, wherein the film-shaped medicament comprises at least one layer containing the cholinergic active agent or the combination of at least two cholinergic active agents and the film-shaped medicament is soluble in aqueous media and/or rapidly disintegrates in aqueous media, but is not mucoadhesive.

15. (Previously Presented) The method according to claim 27, wherein said disease is Alzheimer's disease or the symptom is impaired memory occurring in the course of Alzheimer's disease.

16. (Previously Presented) The method according to claim 27 being a therapy of alcohol abuse.

17. (Previously Presented) The method according to claim 27 being an antidote treatment following neuroleptic anaesthesia.

18. (Previously Presented) The method according to claim 27 being a therapy of abuse of chemical substances or of the dependence on chemical substances.

19. (Previously Presented) The method according to claim 27, wherein the disease or symptom is a symptom of jet lag or another disorder of the physiological rhythm of body functions.

20. (Previously Presented) The method according to claim 27, wherein the disease or symptom is chronic fatigue syndrome or disturbed sleep.

21. (Previously Presented) The method according to claim 27, said disease is schizophrenia or a mania.

22. (Previously Presented) The method according to claim 27, wherein the disease or symptom is a neurological illness and symptom.

23. (Previously Presented) The method according to claim 27, being used for the treatment of disorders of the central nervous system occurring as a consequence of the action of psychotropic substances caused by occasional or chronic use or abuse of addictive substances, narcotics or medicaments, or as a side effect of the use of medicaments as intended, or as a consequence of acute poisoning, or as a consequence of the chronic action of poisons, in humans or other vertebrates.

24. (Previously Presented) The method according to claim 23, wherein the disease or symptom is selected from the group consisting of cognitive disorders, impairment of memory performance, impaired perception, and impaired coordination of movements.

25-26. (Cancelled)

27. **(Currently Amended)** A method of treating a disease or symptom accompanied or caused by a lack of acetylcholine-induced conduction and/or a disturbed regulation of a neuronal nicotinic receptor in a subject, the method comprising buccally administering to the subject a film-shaped medicament, the medicament comprising a therapeutically effective dose of at least one cholinergic active agent or a combination of at least two cholinergic active agents, the cholinergic active agent(s) being selected from the group consisting of galanthamine, pharmaceutically acceptable salts of galanthamine, galanthamine derivatives and their pharmaceutically acceptable salts, wherein within thirty minutes after the buccal administration of the medicament, the medicament releases such an amount of the cholinergic active substance(s) contained therein to the oral cavity of the subject that an effective plasma level is achieved.

28. (Previously Presented) The film-shaped medicament according to claim 2, wherein the polymer content is 15 to 75%-wt.

29. (Previously Presented) The film-shaped medicament according to claim 2, wherein the polymer content is 20 to 50%-wt.

30. (Previously Presented) The film-shaped medicament according to claim 3, wherein the effective plasma level is achieved within 15 min after the application of the medicament to the oral cavity.

31. (Previously Presented) The film-shaped medicament according to claim 3, wherein the effective plasma level is achieved within 5 min after the application of the medicament to the oral cavity.

32. (Previously Presented) The film-shaped medicament according to claim 9, wherein the active substance content is 1 to 20%-wt.

33. (Previously Presented) The film-shaped medicament according to claim 10, wherein the

further pharmaceutically active substance is selected from the group consisting of acetylcholinesterase inhibitors.

34. (Previously Presented) The film-shaped medicament according to claim 11, wherein the thickness of the layer is 0.03 to 2 mm.

35. (Previously Presented) The film-shaped medicament according to claim 11, wherein the thickness of the layer is 0.05 to 1 mm.

36. (Previously Presented) The method according to claim 16 being a treatment for reducing the craving for alcohol or a therapy of nicotine abuse.

37. (Previously Presented) The method according to claim 36 being a treatment for reducing the craving for nicotine.

38. (Previously Presented) The method according to claim 18 being a therapy for intoxication with psychotropic substances.

39. (Previously Presented) The method according to claim 22, wherein the disease or symptom is a paralytic symptom.

40. (Previously Presented) The method according to claim 23, being used for the treatment of disorders of the central nervous system occurring as a side effect of repeated or prolonged use of medicaments in humans or other vertebrates.

41. (Previously Presented) The method according to claim 24, wherein the cognitive disorder is impaired memory.